Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CBi receptor antagonist AVE1625

Journal of Psychopharmacology

Volumn 24, Issue 3, 2010, Pages 363-371

  Zuurman, L ^a   Roy, C ^b   Schoemaker, R C ^a   Amatsaleh, A ^a   Guimaeres, L ^a   Pinquier, J L ^b   Cohen, A F ^a   Van Gerven, J M A ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b SANOFI   (France)

Author keywords

AVE1625; Cannabinoid; Cannabis; Cb1 antagonist; Healthy volunteers; Human; Pharmacodynamics; THC; Volcano vaporiser

Indexed keywords

CANNABINOID 1 RECEPTOR ANTAGONIST; DRINABANT; DRONABINOL; PLACEBO; CANNABINOID 1 RECEPTOR; HALOGENATED HYDROCARBON; SULFONAMIDE; TETRAHYDROCANNABINOL;

ADULT; ALERTNESS; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG PENETRATION; ELECTROENCEPHALOGRAPHY; EMOTIONALITY; FATIGUE; HEART RATE; HUMAN; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; PERCEPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; ADOLESCENT; BODY EQUILIBRIUM; DOSE RESPONSE; DRUG ANTAGONISM; DRUG INTERACTION; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; CENTRAL NERVOUS SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROENCEPHALOGRAPHY; HEART RATE; HUMANS; HYDROCARBONS, HALOGENATED; MALE; POSTURAL BALANCE; RECEPTOR, CANNABINOID, CB1; SULFONAMIDES; TETRAHYDROCANNABINOL;

EID: 77953047693     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108096509     Document Type: Article

References (29)

1. Benarroch, E (2007) Endocannabinoids in basal ganglia circuits: implications for Parkinson disease. Neurology 69: 306-309.
2. Bond, A, Lader, M (1974) The use of analogue scales in rating subjective feelings. Br J Med. Psychol 47: 211-218.
3. Bowdle, TA, Radant, AD, Cowley, DS, Kharasch, ED, Strassman, RJ, Roy-Byrne, PP (1998) Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 88: 82-88. (Pubitemid 28053258)
4. Burns, HD, Van Laere, K, Sanabria-Bohorquez, S, Hamill, TG, Bormans, G, Eng, WS, et al. (2007) [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A 104: 9800-9805.
5. Cahill, K, Ussher, M (2007) Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev: CD005353.
6. Casswell, S (1975) Cannabis intoxication: effects of monetary incentive on performance, a controlled investigation of behavioural tolerance in moderate users of cannabis. Percept Mot Skills 41: 423-434.
7. Choi, YH, Hazekamp, A, Peltenburg-Looman, AM, Frederich, M, Erkelens, C, Lefeber, AW, et al. (2004) NMR assignments of the major cannabinoids and cannabiflavonoids isolated from flowers of Cannabis sativa. Phytochem Anal 15: 345-354.
8. Cooper, SJ (2004) Endocannabinoids and food consumption: comparisons with benzodiazepine and opioid palatability-dependent appetite. Eur J Pharmacol 500: 37-49.
9. DSouza, DC, Abi-Saab, WM, Madonick, S, Forselius-Bielen, K, Doersch, A, Braley, G, et al. (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57: 594-608. (Pubitemid 40409699)
10. DSouza, DC, Perry, E, MacDougall, L, Ammerman, Y, Cooper, T, Wu, YT, et al. (2004) The psychotomimetic effects of intravenous delta-9- tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29: 1558-1572.
11. Di Forti, M, Morrison, PD, Butt, A, Murray, RM (2007) Cannabis use and psychiatric and cogitive disorders: the chicken or the egg. Curr Opin Psychiatry 20: 228-234. (Pubitemid 46588294)
12. Elsohly, MA, Slade, D (2005) Chemical constituents of marijuana: the complex mixture of natural cannabinoids, Life Sci 78: 539-548.
13. Fernandez-Espejo, E, Caraballo, I, de Fonseca, FR, El Banoua, F, Ferrer, B, Flores, JA, et al. (2005) Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol Dis 18: 591-601.
14. Hazekamp, A, Peltenburg, A, Verpoorte, R, Giroud, C (2005) Chromatographic and spectroscopic data of cannabinoids from Cannabis sativa L. J Liq Chromatogr Relat Technol 28: 2361-2382.
15. Hazekamp, A, Ruhaak, R, Zuurman, L, van Gerven, J, Verpoorte, R (2006) Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci 95: 1308-1317. (Pubitemid 43874444)
16. Hazekamp, A, Simons, R, Peltenburg-Looman, AMG, Sengers, M, van Zweden, R, Verpoorte, R (2004) Preparative isolation of cannabinoids from cannabis sativa by centrifugal partitioning chromatography. J Liq Chromatogr Relat Technol 27: 2421-2440.
17. Huestis, MA, Boyd, SJ, Heishman, SJ, Preston, KL, Bonnet, D, Le Fur, G, et al. (2007) Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) 194: 505-515. (Pubitemid 47492992)
18. Huestis, MA, Gorelick, DA, Heishman, SJ, Preston, KL, Nelson, RA, Moolchan, ET, et al. (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58: 322-328.
19. Meltzer, HY, Arvanitis, L, Bauer, D, Rein, W (2004) Placebocontrolled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161: 975-984.
20. Mesnage, V, Houeto, JL, Bonnet, AM, Clavier, I, Arnulf, I, Cattelin, F, et al. (2004) Neurokinin, B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol 27: 108-110. (Pubitemid 38746008)
21. Naef, M, Russmann, S, Petersen-Felix, S, Brenneisen, R (2004) Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. J Pharm Sci 93: 1176-1184.
22. Norris, H (1971) The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 10: 181-191.
23. Pertwee, RG (1999) Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. Life Sci 65: 597-605.
24. Strougo, A, Zuurman, L, Roy, C, Pinquier, JL, Cohen, AF Gerven, JMAv, et al. Modelling of the concentration-effect relationship of THC on central nervous system parameters and heart rate - insight into its mechanisms of action and a tool for clinical research and development of cannabinoids (accepted August 2007 by Journal of Psychopharmacology).
25. Van Gaal, LF, Rissanen, A, Scheen, AJ, Ziegler, O, Rossner, S (2005a) Effect of rimonabant on weight reduction and cardiovascular risk - Authors' reply. Lancet 366: 369-370.
26. Van Gaal, LF, Rissanen, AM, Scheen, AJ, Ziegler, O, Rossner, S (2005b) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365: 1389-1397. (Pubitemid 40523733)
27. Wright, BM (1971) A simple mechanical ataxia-meter. J Physiol 218: 27P-28P.
28. Zavitsanou, K, Garrick, T, Huang, XF (2004) Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28: 355-360.
29. Zuurman, L, Roy, C, Schoemaker, R, Hazekamp, A Hartigh, Jd, Bender, J, et al. (2008) Effect of intrapulmonary THC administration in humans (accepted August 2007 by Journal of Psychopharmacology).